Group 1: Medical Devices Industry - The cardiovascular medical device industry has significant growth potential, with the market for cardiac electrophysiology devices in China expected to grow from CNY 65.80 billion in 2021 to CNY 157.26 billion by 2025, and further to CNY 419.73 billion by 2032 [5][6] - The global market for cardiac rhythm management devices increased from USD 9.7 billion in 2016 to USD 10.6 billion in 2021, with a projected growth to USD 12.8 billion by 2030 [5] - The market for coronary artery disease devices in China is also expanding, with the number of patients expected to reach 31.67 million by 2030, and the market for aortic stent grafts projected to grow significantly [6][7] Group 2: AI Cooling Industry - The AI computing upgrade is driving innovation in cooling technologies, with liquid cooling expected to reduce data center energy consumption by 20%-30%, achieving a PUE below 1.2 [8][9] - The liquid cooling market in China is projected to reach USD 1.26 billion in the first half of 2024, with cold plate solutions currently dominating the market due to their maturity and lower infrastructure modification requirements [9][10] - The market for immersion cooling fluids is expected to grow, with silicone oil and fluorinated liquids being key players, although regulatory challenges may arise [10] Group 3: Semiconductor Industry - Aojie Technology (688220.SH) is a leading player in the baseband chip market, with projected revenues of CNY 45.80 billion, CNY 57.35 billion, and CNY 70.72 billion for 2025, 2026, and 2027 respectively [12][13] - The company has a strong presence in both mobile baseband and IoT sectors, with significant growth expected in its ASIC business, which is anticipated to see multiple-fold growth by 2026 [12][14] Group 4: Pharmaceutical Industry - Lifang Pharmaceutical (003020.SZ) is expected to achieve revenues of CNY 18.53 billion, CNY 22.93 billion, and CNY 27.37 billion from 2025 to 2027, with a strong growth trajectory driven by its unique traditional Chinese medicine products [16][17] - The company is set to launch its first generic version of methylphenidate extended-release tablets in April 2025, targeting a large ADHD market in China [17] Group 5: Beverage Industry - IFBH (6603.HK) is positioned to capture a significant share of the coconut water market in China, which is expected to grow at a CAGR of 55% from 2019 to 2025 [19][20] - The company has established a strong brand presence and is leveraging its supply chain advantages to maintain a competitive edge in the market [20] Group 6: Nonferrous Metals Industry - Zhongmin Resources (002738.SZ) is projected to achieve net profits of CNY 6.03 billion, CNY 12.72 billion, and CNY 22.64 billion from 2025 to 2027, driven by its high-margin cesium and rubidium salt business [22][23] - The company is strategically expanding its copper business, which is expected to provide significant growth potential as demand for copper increases [23][24] Group 7: Aerospace Industry - The commercial aerospace sector is anticipated to reach a turning point with increased satellite launches and the development of reusable rockets, which are critical for the growth of satellite internet [29][30] - Companies like Blue Arrow Aerospace and Tianbing Technology are making significant advancements in rocket technology, with planned launches that could enhance China's capabilities in commercial space [30][31]

事件：9 月23 日至26 日，全球石材行业顶级盛会——意大利维罗纳国际石材展览会（MARMO+MAC） 盛大启幕。公司携性能领先的"线锯设备+金刚线"成套切割解决方案首次亮相展会，向世界彰显中国高 端装备制造的硬核技术实力与创新成果，吸引了全球20 余个国家客商的关注与咨询洽谈。 营收利润逐步向好，有望迎来业绩拐点。25Q2 公司实现营业收入7.66 亿元，环比提升11.63%；实现归 母净利润-0.14 亿元，环比提升80.56%，环比实现大幅减亏，主要系公司克服光伏行业下行周期带来的 重大不利影响，对内深耕降本增效，对外聚焦市场，实现金刚线业务、硅片及切割加工服务业务盈利能 力逐步修复，有望迎来业绩拐点。 光伏切割全链条业务覆盖，技术闭环优势显著。公司是国内率先实现"设备+耗材+代工"三位一体融合 发展的企业。(1)切片耗材：公司冷拉钨丝母线产能快速扩充，市占率快速提升，盈利能力逐步修复。 25H1 公司实现金刚线销量（含自用）约3030 万公里，其中钨丝金刚线约2342 万公里，占比约 77.29%。（2）切片代工：公司硅片切片代工业务订单稳步增长，开工率大幅优于行业并持续提升。公 司25H1 硅片产 ...